PURPOSE/ OBJECTIVES: To estimate and compare responsiveness of standardized self-reported measures of musculoskeletal symptoms (MSSs) and physical functioning (PF) during treatment with aromatase inhibitors (AIs). DESIGN: Prospective, longitudinal study. SETTING: Park Nicollet Institute and North Memorial Cancer Center, both in Minneapolis, MN. SAMPLE: 122 postmenopausal women with hormone receptor-positive breast cancer. METHODS: MSSs and PF were assessed before starting AIs and at one, three, and six months using six self-reported MSSs measures and two PF tests. MAIN RESEARCH VARIABLES: MSSs and PF changes from baseline to six months. FINDINGS: Using the Breast Cancer Prevention Trial-Musculoskeletal Symptom (BCPT-MS) subscale, 54% of participants reported MSSs by six months. Scores from the BCPT-MS subscale and the physical function subscales of the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) and Western Ontario and McMaster Osteoarthritis Index (WOMAC) were most responsive to changes over six months. CONCLUSIONS: BCPT-MS, AUSCAN, and WOMAC were the most responsive instruments for measuring AI-associated MSSs. IMPLICATIONS FOR NURSING: Assessment and management of MSSs are important aspects of oncology care because MSSs can affect functional ability and AI adherence. KNOWLEDGE TRANSLATION: The three measures with the greatest sensitivity were the BCPT-MS, AUSCAN, and WOMAC questionnaires. These measures will be useful when conducting research on change in MSSs associated with AI treatment in women with breast cancer.
PURPOSE/ OBJECTIVES: To estimate and compare responsiveness of standardized self-reported measures of musculoskeletal symptoms (MSSs) and physical functioning (PF) during treatment with aromatase inhibitors (AIs). DESIGN: Prospective, longitudinal study. SETTING: Park Nicollet Institute and North Memorial Cancer Center, both in Minneapolis, MN. SAMPLE: 122 postmenopausal women with hormone receptor-positive breast cancer. METHODS: MSSs and PF were assessed before starting AIs and at one, three, and six months using six self-reported MSSs measures and two PF tests. MAIN RESEARCH VARIABLES: MSSs and PF changes from baseline to six months. FINDINGS: Using the Breast Cancer Prevention Trial-Musculoskeletal Symptom (BCPT-MS) subscale, 54% of participants reported MSSs by six months. Scores from the BCPT-MS subscale and the physical function subscales of the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) and Western Ontario and McMaster Osteoarthritis Index (WOMAC) were most responsive to changes over six months. CONCLUSIONS: BCPT-MS, AUSCAN, and WOMAC were the most responsive instruments for measuring AI-associated MSSs. IMPLICATIONS FOR NURSING: Assessment and management of MSSs are important aspects of oncology care because MSSs can affect functional ability and AI adherence. KNOWLEDGE TRANSLATION: The three measures with the greatest sensitivity were the BCPT-MS, AUSCAN, and WOMAC questionnaires. These measures will be useful when conducting research on change in MSSs associated with AI treatment in women with breast cancer.
Authors: Alice C Shapiro; Susan A Adlis; Kim Robien; Mark N Kirstein; Shuang Liang; Sara A Richter; Rachel E Lerner Journal: Breast Cancer Res Treat Date: 2016-02-11 Impact factor: 4.872
Authors: Marina M Reeves; Caroline O Terranova; Jane M Erickson; Jennifer R Job; Denise S K Brookes; Nicole McCarthy; Ingrid J Hickman; Sheleigh P Lawler; Brianna S Fjeldsoe; Genevieve N Healy; Elisabeth A H Winkler; Monika Janda; J Lennert Veerman; Robert S Ware; Johannes B Prins; Theo Vos; Wendy Demark-Wahnefried; Elizabeth G Eakin Journal: BMC Cancer Date: 2016-10-28 Impact factor: 4.430
Authors: Marina M Reeves; Caroline O Terranova; Elisabeth A H Winkler; Nicole McCarthy; Ingrid J Hickman; Robert S Ware; Sheleigh P Lawler; Elizabeth G Eakin; Wendy Demark-Wahnefried Journal: Nutrients Date: 2021-11-15 Impact factor: 5.717
Authors: Jessica A Martinez; Mihra S Taljanovic; Andres A Nuncio Zuniga; Betsy C Wertheim; Denise J Roe; Sima Ehsani; Sao Jiralerspong; Jennifer Segar; Pavani Chalasani Journal: J Clin Med Date: 2022-02-18 Impact factor: 4.241
Authors: Sameh Gomaa; Carly West; Ana Maria Lopez; Tingting Zhan; Max Schnoll; Maysa Abu-Khalaf; Andrew Newberg; Kuang-Yi Wen Journal: JMIR Form Res Date: 2022-06-21